Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 16,135 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorders Clear all

Conditions: Breast Cancer
Interventions: Positron Emission Mammography (PEM) and Magnetic Resonance Imaging (MRI); Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Drug-induced Nausea and Vomiting
Interventions: acupressure therapy, management of therapy complications, nausea and vomiting therapy; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 2
States / cities: Tampa, Florida • Houston, Texas

Conditions: Solid Tumor, Ovarian Cancer, Breast Cancer
Interventions: Kidney Function Test; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: SRG-514; Drug
Lead sponsor: SURGE Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 8
States / cities: Savannah, Georgia • Indianapolis, Indiana • Rochester, Minnesota + 5 more

Conditions: Lupus Erythematosus, Systemic
Interventions: epratuzumab; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 3
States / cities: New York, New York • Pittsburgh, Pennsylvania • Charleston, South Carolina

Conditions: Breast Cancer
Interventions: cyclophosphamide, docetaxel, doxorubicin hydrochloride; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 69 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Osteoarthritis of the Knee
Interventions: HP-5000 Topical Patch, HP-5000 Placebo Patch, Saline Patch; Drug
Lead sponsor: Noven Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Metastatic Breast Cancer
Interventions: Nurse AMIE (Addressing Metastatic Individuals Every day); Behavioral
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Rheumatoid Arthritis
Interventions: ACTHAR gel; Drug
Lead sponsor: Dana Ascherman; Other
Eligibility: 18 Years to 100 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hand Eczema
Interventions: Ruxolitinib cream, Vehicle; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 23
States / cities: Phoenix, Arizona • Fountain Valley, California • Huntington Beach, California + 18 more

Conditions: Melanoma
Interventions: Montanide ISA 51; Biological
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: DCIS, Breast Cancer, Breast Neoplasms, Sentinel Lymph Node
Interventions: Delayed SLND, Late SLND; Diagnostic Test
Lead sponsor: Uppsala University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Xerostomia, Graft-versus-host-disease, Sjogren's Disease
Interventions: Mesenchymal Stromal Cells (MSC) Dose Level 0, Mesenchymal Stromal Cells (MSC) Dose Level 1; Biological
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 90 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Breast Cancer, Arthralgia
Interventions: Education and exercise intervention, Education and General Exercise; Behavioral
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: MPS III B
Interventions: AX 250; Drug
Lead sponsor: Allievex Corporation; Industry
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Oakland, California • Pittsburgh, Pennsylvania

Conditions: Ductal Breast Carcinoma In Situ, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer
Interventions: Contrast-enhanced Magnetic Resonance Imaging, Mammography, Therapeutic Conventional Surgery, Ultrasonography, Gadolinium; Procedure · Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Disorders of Breast
Interventions: Exercise, Questionnaires, Motivational Session, Phone Call, Printed Materials; Other · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Rheumatoid Arthritis, Osteoarthritis, Post-traumatic Arthritis, Avascular Necrosis
Interventions: Alumina/Alumina, Standard; Device
Lead sponsor: Encore Medical, L.P.; Industry
Eligibility: 18 Years and older
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2015
U.S. locations: 3
States / cities: Newport Beach, California • Charleston, South Carolina • Richmond, Virginia

Conditions: Cancer
Interventions: Rosuvastatin10 mg tablet, Midazolam 3 mg syrup, Dabrafenib 75 mg capsule; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Breast Cancer, Lung Cancer, Prostate Cancer
Interventions: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell), Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo, Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).; Dietary Supplement · Drug
Lead sponsor: Optimal Health Research; Other
Eligibility: 25 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Breast Cancer
Interventions: Physical Activity; Other
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years to 74 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Kawasaki Disease
Interventions: Sestamibi; Drug
Lead sponsor: Lantheus Medical Imaging; Industry
Eligibility: 4 Years to 16 Years
Enrollment: 445 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 29
States / cities: Anchorage, Alaska • Little Rock, Arkansas • Los Angeles, California + 25 more

Conditions: Breast Cancer
Interventions: 3-D Optical Surface Scan, Mechanical Testing, Cutaneous Ultrasound, Breast MRI and/or CT; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer, Melanoma, Solid Tumor, Squamous Cell Carcinoma of Head and Neck, Breast Cancer, Advanced Solid Tumor, Triple Negative Breast Cancer, Colorectal Carcinoma, Non-melanoma Skin Cancer, Liver Metastases
Interventions: ONCR-177, pembrolizumab; Biological
Lead sponsor: Oncorus, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 10
States / cities: Duarte, California • Denver, Colorado • Tampa, Florida + 6 more

Search by objective public record fields.

Histologic Assessment of the Difference Between 18F-2-fluoro-2-deoxy_D-glucose Positron Emission Mammography(PEM) and Magnetic Resonance Imaging (MRI) of the Breast

Acupressure in Treating Nausea in Women Receiving Combination Chemotherapy for Breast Cancer

Effect of PARP Inhibitors on Glomerular Filtration Rate

SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery

Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)

Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer

Irritation and Sensitization Study of HP-5000 Topical System

Nurse AMIE for Echo Show: Randomized Control Trial

ACTH Gel Therapy in Rheumatoid Arthritis

Topical Ruxolitinib Evaluation in Chronic Hand Eczema

Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma

Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ

Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia

The CEASE Study: Computer Based Educational Module for the Reduction of Arthralgia Syndrome Associated With Endocrine Therapy for Breast Cancer

Safety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLE

Extent of Breast Cancer and the Role of Pre-Operative Sonography and MRI

High-Intensity Interval Training for Women at Heightened Risk for Breast Cancer

Cementless Alumina-Alumina Total Hip and Hybrid

Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam

A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.

Effects of a Structured Exercise Program on Cancer-Related Fatigue in Women Receiving Radiation Therapy for Breast Cancer

A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease

3-Dimensional Form and Soft Tissue Biomechanics of the Breast

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors